Hereditary Cancer Screening | Kailos
 
 

Hereditary Cancer Screening

TargetRich Hereditary Cancer Screening

The number of clinicians that understand the value of hereditary cancer screening is rapidly growing. This is bolstered by patient demand and new treatments that leverage screening insights to improve efficacy.

Hereditary Cancer Screening from Kailos Genetics lets you easily perform a next-generation sequencing assay designed to cover genes associated with multiple types of hereditary cancer risks for:

  • Breast
  • Ovarian
  • Colon
  • Uterine
  • Prostate
  • Pancreatic
  • And more…

The Hereditary Cancer Screening panel is an enrichment-based targeted panel covering a wide range of genes. This comprehensive panel provides laboratories with a deep view into the genetic risks of cancer development. The Hereditary Cancer Screening panel offers:

 

  • Broad Coverage – Assessments of insertions/deletions and single-nucleotide variants (SNVs) in 32 genes associated with multiple types of heritable cancers.
  • Sample Flexibility – Variant detection from a wide-variety of sample collection methods including buccal swabs, blood, mouthwash and saliva.
  • Streamlined Workflow – PCR-free target capture enables the preparation of samples manually or with most standard laboratory automation systems.
  • Multiplexing and Rapid Sample Processing – Support for simultaneously processing up to 96 samples with standard lab equipment. 

 

Assay Target Summary
APC BRCA2 EPCAM MSH2 PMS2 RINT1 VHL
ATM BRIP1 FH MSH6 PTEN SDHB XRCC2
BARD1 CDH1 FLCN MUTYH RAD50 SMAD4  
BMPR1A CDKN2A MLH1 NBN RAD51C STK11  
BRCA1 CHEK2 MRE11A PALB2 RAD51D TP53  

 

Product Catalog Number Description Documents Price
KG-9021 TargetRichTM: Hereditary Cancer 96 Reactions TargetRich™ Hereditary Cancer Panel Contact for Quote
KG-9027 TargetRichTM: UMI/Sample Adapters TargetRich™ UMI/Index Adapters for Hereditary Cancer Panel Contact for Quote
 

Start-up and volume based pricing available.
For Research Use Only, Not FDA Approved

 

Sequencing Specifications

Sequencer Compatibility: Illumina MiSeq, MiniSeq, NextSeq, HiSeq

Read Lengths: 2 x 150 cycles

Index Reads: Sample Specific (8 cycles) & Unique Molecular Identifiers (12 cycles)

Hereditary Cancer Screening

Maximize the results of TargetRich Hereditary Cancer Screening with the industry’s most advanced computing and reporting infrastructure. Learn more about Kailos Blue Analytics Solutions and Kailos Blue Reporting Solutions.

For more information, contact us here.